The Future of the Nephrology Drugs Market: Growth Trends, Market Size, and Opportunities to Watch
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Industry-Specific Factors Are Fueling the Growth of the Nephrology Drugs Market?
The increase in chronic kidney disease cases anticipated to fuel the expansion of the market for nephrology drugs. Chronic kidney disease (CKD) is a condition where the kidneys are damaged and cannot effectively perform their function of blood filtration. This damage happens progressively over a prolonged period, which may lead to waste accumulating in the body. The primary purpose of nephrology drugs is to treat chronic kidney disease, enhance the functioning of the kidneys, and slow down the progression of the disease, hence preventing more damage to the body. This scenario thereby stimulates the nephrology drugs market growth. For example, it was reported by the US-based Centers for Disease Control and Prevention (CDC) in July 2022, that over 37 million people in the US have been diagnosed with chronic kidney disease, a condition particularly prevalent in people aged 65 years or older at 38%. Additionally, the Canada-based Kidney Foundation of Canada reported that 4 million Canadians are suffering from kidney diseases. With diabetic patients constituting 35%, they are the prime causes of kidney failure. Thus, the escalating prevalence of chronic kidney disease is spurring the growth of the nephrology drug market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp
#What Are the Key Projections for the CAGR of the Nephrology Drugs Market From 2025 to 2034?
In recent times, there has been a robust expansion in the size of the nephrology drugs market. This growth is projected to continue, seeing an increase from $16.88 billion in 2024 to $17.86 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. Factors such as the increasing rates of chronic kidney diseases (CKD), advances in drug creation, heightened awareness and diagnosis, government-driven initiatives, and healthcare policies, along with a rise in diabetes cases, substantially contributed to this historic growth period.
The market for nephrology drugs is projected to experience robust expansion in the coming years, increasing to $23.04 billion by 2029 at a compound annual growth rate (CAGR) of 6.6%. This surge over the forecast period can be associated with the advent of new therapies and drug developments, precision medication, tailored treatment strategies, amplified healthcare expenditures, telehealth, and remote patient supervision, as well as international health strategies. Noteworthy trends during this forecast period encompass collaborations and alliances, technological progress in dialysis, advancements in treatment methods, an increasing focus on early detection and intervention, and technological incorporation in nephrology management.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10076
What Key Market Trends and Innovations Are Shaping the Future of the Nephrology Drugs Industry?
Pioneering new products is a leading trend making waves in the nephrology medicine market. Key businesses in this market are creating fresh and innovative drugs to retain their grip on the market. For instance, Zydus Lifesciences Limited, a pharmaceutical company based in India, unveiled Oxemia (desidustat) in March 2022, a drug for chronic kidney disease (CKD). This orally administered, small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor presents a practical treatment alternative for anaemia and has received the green light from the Drug Controller General of India after Phase III clinical trials. The drug has shown to have a sound safety profile, effectively reduces hepcidin, improves iron mobilization, and cuts down LDL-C in patients with chronic kidney disease. Additionally, offering this treatment at a fair price will improve the patients’ quality of life and alleviate the disease’s impact.
Which Companies Are Leading the Charge in Expanding the Nephrology Drugs Market Growth?
Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report
How is the Global Nephrology Drugs Market Segemented?
The nephrology drugs market covered in this report is segmented –
1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)
2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa
3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics
4) By ACE Inhibitors: Lisinopril, Enalapril
5) By Antidiabetic Agents: Metformin, Insulin
6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp
Which Geographics are Influencing the Growth of the Nephrology Drugs Market?
North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Gobal Nephrology Drugs Maret 2025, By The Business Research Company:
Drug Delivery Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report
Drugs For Erectile Dysfunction Global Market Report 2024
Drugs For Benign Prostatic hypertrophy Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
